Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for cardioprotection in doxorubicin-treated breast cancer
IRCT20260429069203N1Phase 3Completed
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in breast cancer and heart failure (HF), sponsored by Kermanshah University of Medical Sciences. Primary endpoint: cardiac function. Started May 2026; status: completed.
02
Drugs
empagliflozin
03
Conditions
breast cancerheart failure (HF)
Beyond the preview
Go deeper on IRCT20260429069203N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260429069203N1.